A new nasal delivery method for amifostine could protect healthy tissue during pancreatic cancer radiation therapy, ...

A new drug delivery system shows promise for treating a rare, aggressive form of cancer affecting pregnant women and new mothers, and it has potential with other cancers as well.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

Microbes that reside peaceably in the nasal passageways and on the skin can be harnessed for taking drugs to target cells.

The global drug delivery solutions market is poised for significant growth, with an estimated value of USD 113.3 million in ...

Researchers at University of the Pacific in Stockton have developed a long-acting opioid overdose-reversal drug-delivery system that could save lives.

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

LONDON, GREATER LONDON, UNITED KINGDOM, January 31, 2025 /EINPresswire / -- Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Raanana, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a biotech firm in the development stage, has filed a divisional patent application in Israel for its Trap & Target (NYSE:TGT) (T&T) platform technology.

Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced the filing of a ...

Polyrizon (PLRZ) announced the filing of a divisional patent application with the Israel Patent Office for its Trap & Target platform ...